TTOO vs. LYRA, STIM, KRMD, BLUA, BWAY, SRTS, HSAQ, ALUR, PDEX, and NVNO
Should you be buying T2 Biosystems stock or one of its competitors? The main competitors of T2 Biosystems include Lyra Therapeutics (LYRA), Neuronetics (STIM), KORU Medical Systems (KRMD), BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), and enVVeno Medical (NVNO). These companies are all part of the "surgical & medical instruments" industry.
T2 Biosystems (NASDAQ:TTOO) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
T2 Biosystems presently has a consensus target price of $3.00, indicating a potential downside of 41.63%. Lyra Therapeutics has a consensus target price of $7.13, indicating a potential upside of 2,072.26%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than T2 Biosystems.
T2 Biosystems has higher revenue and earnings than Lyra Therapeutics.
T2 Biosystems has a beta of 0.05, meaning that its share price is 95% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.
In the previous week, Lyra Therapeutics had 1 more articles in the media than T2 Biosystems. MarketBeat recorded 3 mentions for Lyra Therapeutics and 2 mentions for T2 Biosystems. T2 Biosystems' average media sentiment score of 0.83 beat Lyra Therapeutics' score of -0.02 indicating that T2 Biosystems is being referred to more favorably in the media.
23.2% of T2 Biosystems shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 0.1% of T2 Biosystems shares are held by insiders. Comparatively, 17.4% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
T2 Biosystems received 384 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 64.65% of users gave T2 Biosystems an outperform vote while only 61.11% of users gave Lyra Therapeutics an outperform vote.
T2 Biosystems has a net margin of -636.09% compared to Lyra Therapeutics' net margin of -4,099.82%. T2 Biosystems' return on equity of 0.00% beat Lyra Therapeutics' return on equity.
Summary
Lyra Therapeutics beats T2 Biosystems on 8 of the 15 factors compared between the two stocks.
Get T2 Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TTOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
T2 Biosystems Competitors List
Related Companies and Tools
